2015 ACVIM Forum Research Abstract Program

This study evaluated the safety, progression-free survivals (PFS), and overall survival (OS) of combining an abbreviated protocol of L-asparaginase and doxorubicin with MAb to treat B-cell lymphoma. Dogs (n = 20) with newly diagnosed B-cell lymphoma and measurable peripheral lymph node enlargement were enrolled in this prospective, open-label study. In Phase 1 subjects were treated with three doses of doxorubicin (30 mg/m 2 ) once every three weeks and seven doses of MAb (5 mg/kg) over a period of fourteen weeks. At relapse, nine of the eleven dogs who were eligible to participate in Phase 2 were treated with an additional dose of doxorubicin (30 mg/m 2 ) and four doses of MAb (5 mg/kg). Two of the dogs treated in Phase 1 never relapsed, one of which is still alive (OS: 790 days). At the start of both Phase 1 and 2, dogs were able to receive 1 dose of L-asparaginase. Nineteen of the twenty dogs enrolled received treatment with MAb (125 total treatments; 1 dog withdrew prior to MAb administration). Three of the dogs administered MAb experienced MAb infusion-related reactions (1 reaction/dog). One of the twenty dogs administered doxorubicin (60 total treatments) experienced doxorubicin toxicity after the third dose of doxorubicin.